Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events
Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Qu, Tailong, Chen, Na, Ma, Shun, He, Xinrong, Xia, Dennis, Wang, Max, Xia, Michelle, Li, Baiyong
Published in Frontiers in immunology (27.06.2022)
Published in Frontiers in immunology (27.06.2022)
Get full text
Journal Article
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
Qu, Tailong, Zhong, Tingting, Pang, Xinghua, Huang, Zhaoliang, Jin, Chunshan, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Yu
Published in Journal for immunotherapy of cancer (01.11.2022)
Published in Journal for immunotherapy of cancer (01.11.2022)
Get full text
Journal Article
1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects
Zhong, Tingting, Huang, Zhaoliang, Pang, Xinghua, Jin, Chunshan, He, Xinrong, Montoya, Jose, Chang, Betty, Xia, Michelle, Li, Baiyong, Min, Jing
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
289 Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone
Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Chen, Na, He, Xinrong, Xia, Dennis, Jin, Xiaoping, Wang, Zhongmin, Xia, Xu, Li, Baiyong
Published in Journal for immunotherapy of cancer (01.11.2021)
Published in Journal for immunotherapy of cancer (01.11.2021)
Get full text
Journal Article
266 AK117, a CD47 blocking antibody with robust macrophage activation without red blood cell hemagglutination
Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Qu, Tailong, Jin, Chunshan, Chen, NA, He, Xinrong, Xia, Dennis, Jin, Xiaoping, Wang, Zhongmin, Xia, Xu, Li, Baiyong
Published in Journal for immunotherapy of cancer (01.11.2021)
Published in Journal for immunotherapy of cancer (01.11.2021)
Get full text
Journal Article
476 AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19
Zhong, Tingting, Huang, Zhaoliang, Pang, Xinghua, Chen, Na, Kwek, Konyew, Wynne, Chris, Konpa, Adam, Jin, Xiaoping, Xia, Yu, Wang, Maxwell Zhongmin, Li, Baiyong
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
Abstract 3827: Bispecific antibodies with an anti-PD-1 backbone for cancer therapy generate enhanced immune activity
Li, Baiyong, Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Chen, Na, Wang, Max, Jin, Xiaoping, Xia, Dennis, Zhang, Peng, Xia, Michelle Yu
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Abstract B123: Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects
Zhong, Tingting, Huang, Zhaoliang, Pang, Xinghua, Jin, Chunshan, He, Xinrong, Montoya, Jose G, Chang, Betty Y, Xia, Michelle, Li, Baiyong, Min, Jing
Published in Molecular cancer therapeutics (01.12.2023)
Published in Molecular cancer therapeutics (01.12.2023)
Get full text
Journal Article
Abstract 5524: AK127, a novel monoclonal antibody (mAb) targeting T cell immunoreceptor (TIGIT)
Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Jin, Chunshan, Chen, Na, Xia, Dennis, Zhang, Peng, Wang, Max, Xia, Michelle, Li, Baiyong
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
Abstract 5520: AK129, an anti-PD1/LAG-3 bi-specific antibody for cancer therapy
Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Jin, Chunshan, Chen, Na, Xia, Dennis, Zhang, Peng, Wang, Max, Xia, Michelle, Li, Baiyong
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
Abstract 5526: AK131, an anti-PD1/CD73 bispecific antibody for cancer immune therapy
Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Jin, Chunshan, Chen, Na, Xia, Dennis, Zhang, Peng, Wang, Max, Xia, Michelle, Li, Baiyong
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
702 Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy
Zhong, Tingting, Huang, Zhaoliang, Pang, Xinghua, Chen, Na, Jin, Xiaoping, Yu, Xia, Zhongmin Maxwell Wang, Li, Baiyong
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
184 Two types of anti-TIGIT antibodies with distinct binding epitope and functional activities
Zhong, Tingting, Pang, Xinghua, Huang, Zhaoliang, Chen, Na, Jin, Xiaoping, Yu, Xia, Maxwell Zhongmin Wang, Li, Baiyong
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
Research on Substation Secondary Cable Path Identification Device
Ding, Jian, Jiang, Linyi, Huang, Zhaoliang
Published in 2023 3rd International Conference on Electrical Engineering and Control Science (IC2ECS) (29.12.2023)
Published in 2023 3rd International Conference on Electrical Engineering and Control Science (IC2ECS) (29.12.2023)
Get full text
Conference Proceeding